Research programme: antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent

Drug Profile

Research programme: antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent

Alternative Names: ANA-conjugated doxorubicin liposomal - NanoSmart/NanoValent; Anti-nuclear antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent; Dox-anti-CD19; Dox-anti-CD99; Doxorubicin liposomal - NanoSmart/NanoValent; NV101 NanoValent; NV102; NV103

Latest Information Update: 17 Nov 2015

Price : $50

At a glance

  • Originator NanoSmart Pharmaceuticals; NanoValent Pharmaceuticals
  • Class Anthracyclines; Doxorubicins; Immunoconjugates; Small molecules
  • Mechanism of Action CD antigen inhibitors; DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Ewing's sarcoma
  • Research Ovarian cancer; Solid tumours

Most Recent Events

  • 17 Nov 2015 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)
  • 17 Nov 2015 Preclinical trials in Acute lymphoblastic leukaemia in USA (unspecified route)
  • 17 Nov 2015 Preclinical trials in Ewing's Sarcoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top